Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin

• DOI: 10.1128/spectrum.00517-23
• Publication Date: 2023-03-28T14:12:08Z
• Authors: Susan P. Sambol; Andrew M. Skinner; Fidel Serna-Perez; Benjamin Owen; Dale N. Gerding; Stuart Johnson
• Keywords: 3. Good health; Research Article

NTCD-M3 is a novel live biotherapeutic, that has been shown in a Phase 2 clinical trial to prevent recurrence of C. difficile infection (CDI) when administered shortly after antibiotic treatment of the initial CDI episode. Fidaxomicin was not, however, in widespread use at the time this study was conducted.